2015
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia
Mohamed S, Rosenheck RA, Lin H, Swartz M, McEvoy J, Stroup S. Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia. The Journal Of Nervous And Mental Disease 2015, 203: 486-492. PMID: 26075840, DOI: 10.1097/nmd.0000000000000317.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlcoholismAntipsychotic AgentsBenzodiazepinesChronic DiseaseComorbidityCross-Sectional StudiesDibenzothiazepinesDouble-Blind MethodFemaleHumansIllicit DrugsMaleMiddle AgedOlanzapinePerphenazinePiperazinesPsychiatric Status Rating ScalesQuetiapine FumarateRisperidoneSchizophreniaSchizophrenic PsychologySmokingSmoking PreventionSubstance-Related DisordersThiazolesYoung AdultConceptsSecond-generation antipsychotic drugsAntipsychotic drugsFirst-generation antipsychoticsSecond-generation antipsychoticsIntervention Effectiveness (CATIE) studySecondary outcome dataClinical Antipsychotic TrialsFirst-generation drugsSubstance use outcomesCigarette smokingSchizophrenia trialsChronic schizophreniaAntipsychotic TrialsOutcome dataNicotine useDrug useSecondary analysisPast weekAntipsychoticsEffectiveness studiesPatientsSubstance useUse outcomesTrialsDrugs
2004
The Use of Novel Antipsychotics in the Older Patient With Neurodegenerative Disorders in the Long-Term Care Setting
Kasckow J, Mulchahey J, Mohamed S. The Use of Novel Antipsychotics in the Older Patient With Neurodegenerative Disorders in the Long-Term Care Setting. Journal Of The American Medical Directors Association 2004, 5: 242-248. PMID: 15228634, DOI: 10.1016/s1525-8610(04)70130-9.Peer-Reviewed Original ResearchConceptsAtypical antipsychoticsRate of extrapyramidal side effectsHigh-potency conventional antipsychoticsDays of risperidoneAtypical antipsychotic medicationsExtrapyramidal side effectsDay of olanzapineDouble-blind placebo-controlled trialConventional antipsychoticsNovel antipsychoticsAntipsychotic medicationTardive dyskinesiaTreating older patientsPsychopharmacological agentsAgitation symptomsNeurodegenerative disordersAntipsychoticsBehavioral agitationPlacebo-controlled trialOpen-label studyOlder patientsHigh-potencyAripiprazoleOlanzapineRisperidone
1999
Will the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia?
HAWKINS KA, MOHAMED S, WOODS SW. Will the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia? Psychological Medicine 1999, 29: 1-8. PMID: 10077288, DOI: 10.1017/s0033291798006990.Peer-Reviewed Original ResearchConceptsNovel antipsychoticsNegative symptomsNeuropsychological deficitsSevere psychiatric illnessNew antipsychotic medicationsTreatment of schizophreniaCognitive outcome dataAntipsychotic medicationConventional neurolepticsNeurodevelopmental aberrationsClinical effectivenessNew antipsychoticsUnderlying pathophysiologyClinical reasonsPsychiatric illnessImproved complianceOutcome dataFunctional capacityNeurological effectsAntipsychoticsAuditory hallucinationsNeurocognitive changesMedicationsNeural tissueSymptoms